Elevated GPX3 expression in endometriosis: implications for pathogenesis and immune cell infiltration

Read full text
Authors: Xiao-gang Mao, Xi Yang, Ya-nan Zhu, Meng-meng Sun, Fan Ye, Shi-ge San, Jian Tang, Liang Shen, Hui Xing, Kun Meng
Cited by: 1
References: 23

Abstract

INTRODUCTION: Endometriosis (EM) is an inflammatory condition that affects approximately 10% of the female-born population. It is characterized by the presence of endometrial tissue outside the uterine cavity, leading to chronic pelvic pain, dysmenorrhea, infertility, and a significant reduction in quality of life. The molecular feature of endometriosis remains poorly understood. MATERIAL AND METHODS: Endometriosis-related transcriptomic datasets from the Gene Expression Omnibus (GEO) were normalized and analyzed, and candidate hub genes were identified using two machine learning algorithms. These protein expressions were further validated using proteomic data derived from clinical ectopic and eutopic endometrial tissue samples. Functional assays, including gene silencing and cell migration experiments, were conducted to investigate their biological roles. RESULTS: Glutathione Peroxidase 3 (GPX3) emerged as a candidate diagnostic protein. Silencing GPX3 significantly reduced the migratory capacity of endometriosis cells, likely through modulation of antioxidant activity. In clinical samples, ectopic lesions with high GPX3 expression exhibited increased immune cell infiltration, particularly showing elevated CD68⁺ macrophages and PD-1-positive T cells. CONCLUSION: Collectively, our findings suggest that GPX3 serves as a potential biomarker for the diagnosis and prognosis of endometriosis, with its expression positively correlating with immune cell infiltration in ectopic endometrial tissue.

Fields of Study & Subjects

Endometriosis Research and Treatment Reproductive System and Pregnancy Gynecological conditions and treatments

Publication details

Journal / source
European journal of medical research
Publisher
Springer Science and Business Media LLC
Volume
31
Issue
1
Pages
250–250
Publication date
11 January 2026
Language
EN